JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Bacteria
Gram-positive and Gram-negative bacteria
Preparation method
The solubility of this compound in DMSO is > 23.9 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months.
Reacting condition
12.5 ~ > 100 μM
Applications
Zafirlukast exhibited antibacterial and antibiofilm activities against Gram-positive bacteria (including the cariogenic pathogen S. mutans) whilst showed no significant activity against Gram-negative bacteria (except for the oral pathogen P. gingivalis). Additional tests showed that Zafirlukast did not cause resistance in S. mutans.
Animal models
A rat model of colitis
Dosage form
40 or 80 mg/kg; orally or rectally; for 3 consecutive days
In a rat model of colitis, pretreatment with Zafirlukast (80 mg/kg, orally) significantly decreased tissue malondialdehyde and myeloperoxidase, and meanwhile, increased the reduced glutathione and catalase levels, whilst there was no significant change when it was given rectally. At the dose of 40 mg/kg dose (orally and rectally), no significant protective effect was observed.
Other notes
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.
References:
[1]. Kassahun K, Skordos K, McIntosh I, Slaughter D, Doss GA, Baillie TA, Yost GS. Zafirlukast metabolism by cytochrome P450 3A4 produces an electrophilic alpha,beta-unsaturated iminium species that results in the selective mechanism-based inactivation of the enzyme. Chem Res Toxicol. 2005 Sep;18(9):1427-37.
[2]. Mahgoub AA, El-Medany AA, Hager HH, Mustafa AA, El-Sabah DM. Evaluating the prophylactic potential of zafirlukast against the toxic effects of acetic acid on the rat colon. Toxicol Lett. 2003 Nov 1;145(1):79-87.
